Non-deletional haemoglobin H (HbH) disease represents a distinct and heterogeneous sub-group within the alpha thalassemia spectrum. Managing patients in this category requires awareness of the variable clinical course and readiness to intervene when haematological thresholds are reached.
Clinical phenotypes are diverse among affected individuals with non-deletional haemoglobin H (HbH) disease (--/αTα), creating a need for individualized clinical assessment and evidence-based criteria to guide intervention.
For patients in this group, red blood cell transfusion is the primary supportive intervention considered when specific haematological criteria are met during acute haemolytic episodes. The full structured protocol — including precise criteria for initiation and clinical targets — is available below.
The primary therapeutic target is restoration of haemoglobin to an adequate level. The exact target range and the evidence supporting it are specified in the full protocol.